S&P 500   3,859.70 (+0.20%)
DOW   31,252.47 (+0.21%)
QQQ   325.64 (+0.58%)
AAPL   135.96 (+2.98%)
MSFT   224.09 (-0.11%)
FB   271.64 (+1.56%)
GOOGL   1,918.97 (+2.07%)
AMZN   3,332.25 (+2.11%)
TSLA   846.20 (-0.50%)
NVDA   543.12 (+1.59%)
BABA   261.05 (-1.67%)
CGC   33.19 (-1.31%)
GE   11.27 (-1.05%)
MU   83.37 (-0.16%)
AMD   90.08 (+1.50%)
NIO   56.65 (-1.84%)
T   28.93 (-0.10%)
F   11.72 (+7.92%)
ACB   11.06 (-4.16%)
BA   208.73 (-1.29%)
DIS   172.43 (-0.70%)
NFLX   581.18 (-0.88%)
GILD   66.91 (-1.59%)
S&P 500   3,859.70 (+0.20%)
DOW   31,252.47 (+0.21%)
QQQ   325.64 (+0.58%)
AAPL   135.96 (+2.98%)
MSFT   224.09 (-0.11%)
FB   271.64 (+1.56%)
GOOGL   1,918.97 (+2.07%)
AMZN   3,332.25 (+2.11%)
TSLA   846.20 (-0.50%)
NVDA   543.12 (+1.59%)
BABA   261.05 (-1.67%)
CGC   33.19 (-1.31%)
GE   11.27 (-1.05%)
MU   83.37 (-0.16%)
AMD   90.08 (+1.50%)
NIO   56.65 (-1.84%)
T   28.93 (-0.10%)
F   11.72 (+7.92%)
ACB   11.06 (-4.16%)
BA   208.73 (-1.29%)
DIS   172.43 (-0.70%)
NFLX   581.18 (-0.88%)
GILD   66.91 (-1.59%)
S&P 500   3,859.70 (+0.20%)
DOW   31,252.47 (+0.21%)
QQQ   325.64 (+0.58%)
AAPL   135.96 (+2.98%)
MSFT   224.09 (-0.11%)
FB   271.64 (+1.56%)
GOOGL   1,918.97 (+2.07%)
AMZN   3,332.25 (+2.11%)
TSLA   846.20 (-0.50%)
NVDA   543.12 (+1.59%)
BABA   261.05 (-1.67%)
CGC   33.19 (-1.31%)
GE   11.27 (-1.05%)
MU   83.37 (-0.16%)
AMD   90.08 (+1.50%)
NIO   56.65 (-1.84%)
T   28.93 (-0.10%)
F   11.72 (+7.92%)
ACB   11.06 (-4.16%)
BA   208.73 (-1.29%)
DIS   172.43 (-0.70%)
NFLX   581.18 (-0.88%)
GILD   66.91 (-1.59%)
S&P 500   3,859.70 (+0.20%)
DOW   31,252.47 (+0.21%)
QQQ   325.64 (+0.58%)
AAPL   135.96 (+2.98%)
MSFT   224.09 (-0.11%)
FB   271.64 (+1.56%)
GOOGL   1,918.97 (+2.07%)
AMZN   3,332.25 (+2.11%)
TSLA   846.20 (-0.50%)
NVDA   543.12 (+1.59%)
BABA   261.05 (-1.67%)
CGC   33.19 (-1.31%)
GE   11.27 (-1.05%)
MU   83.37 (-0.16%)
AMD   90.08 (+1.50%)
NIO   56.65 (-1.84%)
T   28.93 (-0.10%)
F   11.72 (+7.92%)
ACB   11.06 (-4.16%)
BA   208.73 (-1.29%)
DIS   172.43 (-0.70%)
NFLX   581.18 (-0.88%)
GILD   66.91 (-1.59%)
Log in
NASDAQ:CNCE

Concert Pharmaceuticals Stock Forecast, Price & News

$10.73
-0.19 (-1.74 %)
(As of 01/21/2021 10:27 AM ET)
Add
Compare
Today's Range
$10.73
Now: $10.73▼
$10.85
50-Day Range
$10.58
MA: $12.20▼
$13.07
52-Week Range
$5.47
Now: $10.73▼
$13.50
Volume397 shs
Average Volume207,965 shs
Market Capitalization$328.86 million
P/E RatioN/A
Dividend YieldN/A
Beta0.77
Concert Pharmaceuticals, Inc. operates as a clinical stage biopharmaceutical company. The company discovers and develops novel small molecule drugs for the treatment of autoimmune and central nervous system disorders. Its product candidates include CTP-543, which is in Phase III clinical trials for the treatment of alopecia areata; CTP-692, a selective deuterium-modified analog of the endogenous amino acid and D-serine that is in Phase II trials for the treatment of schizophrenia; and AVP-786, a combination of deudextromethorphan and an ultra-low dose of quinidine, which is in Phase 3 clinical trials for the treatment of neurologic and psychiatric disorders, including agitation associated with Alzheimer's disease. The company has strategic collaborations with Avanir Pharmaceuticals, Inc.; Cipla Technologies; Processa Pharmaceuticals; and Jazz Pharmaceuticals, Inc. Concert Pharmaceuticals was founded in 2006 and is headquartered in Lexington, Massachusetts.
Concert Pharmaceuticals logo

MarketRank™

Overall MarketRank™

1.68 out of 5 stars

Medical Sector

236th out of 1,928 stocks

Pharmaceutical Preparations Industry

115th out of 774 stocks

Analyst Opinion: 3.4Community Rank: 2.7Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.6 5 -4 -3 -2 -1 -

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:CNCE
Previous Symbol
CUSIPN/A
CIK1367920
Webwww.concertpharma.com
Phone781-860-0045
Employees70

Debt

Debt-to-Equity RatioN/A
Current Ratio18.51
Quick Ratio18.51

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual Sales$1.08 million
Price / Sales304.50
Cash FlowN/A
Price / Cash FlowN/A
Book Value$4.26 per share
Price / Book2.52

Profitability

EPS (Most Recent Fiscal Year)($3.29)
Net Income$-78,170,000.00
Net Margins-921.38%
Return on Equity-55.20%
Return on Assets-44.83%

Miscellaneous

Outstanding Shares30,649,000
Market Cap$328.86 million
Next Earnings Date2/25/2021 (Estimated)
OptionableOptionable
$10.73
-0.19 (-1.74 %)
(As of 01/21/2021 10:27 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive CNCE News and Ratings via Email

Sign-up to receive the latest news and ratings for CNCE and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Concert Pharmaceuticals (NASDAQ:CNCE) Frequently Asked Questions

How has Concert Pharmaceuticals' stock price been impacted by Coronavirus?

Concert Pharmaceuticals' stock was trading at $8.35 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, CNCE stock has increased by 28.5% and is now trading at $10.73.
View which stocks have been most impacted by COVID-19.

Is Concert Pharmaceuticals a buy right now?

7 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Concert Pharmaceuticals in the last twelve months. There are currently 1 hold rating and 6 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Concert Pharmaceuticals stock.
View analyst ratings for Concert Pharmaceuticals or view MarketBeat's top 5 stock picks.

What stocks does MarketBeat like better than Concert Pharmaceuticals?

Wall Street analysts have given Concert Pharmaceuticals a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Concert Pharmaceuticals wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

What is Doug Parker's approval rating as Concert Pharmaceuticals' CEO?

1,428 employees have rated Concert Pharmaceuticals CEO Doug Parker on Glassdoor.com. Doug Parker has an approval rating of 59% among Concert Pharmaceuticals' employees. This puts Doug Parker in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

When is Concert Pharmaceuticals' next earnings date?

Concert Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Thursday, February 25th 2021.
View our earnings forecast for Concert Pharmaceuticals.

How were Concert Pharmaceuticals' earnings last quarter?

Concert Pharmaceuticals, Inc. (NASDAQ:CNCE) issued its earnings results on Thursday, November, 5th. The biotechnology company reported ($0.60) earnings per share for the quarter, beating the Thomson Reuters' consensus estimate of ($0.75) by $0.15. The biotechnology company had revenue of $1.50 million for the quarter. Concert Pharmaceuticals had a negative net margin of 921.38% and a negative return on equity of 55.20%.
View Concert Pharmaceuticals' earnings history.

What price target have analysts set for CNCE?

7 brokers have issued 12-month price objectives for Concert Pharmaceuticals' stock. Their forecasts range from $11.00 to $30.00. On average, they expect Concert Pharmaceuticals' share price to reach $22.00 in the next year. This suggests a possible upside of 105.0% from the stock's current price.
View analysts' price targets for Concert Pharmaceuticals or view Wall Street analyst' top-rated stocks.

Who are some of Concert Pharmaceuticals' key competitors?

Some companies that are related to Concert Pharmaceuticals include MacroGenics (MGNX), Dyne Therapeutics (DYN), Applied Molecular Transport (AMTI), Innoviva (INVA), Frequency Therapeutics (FREQ), Kiniksa Pharmaceuticals (KNSA), Antibe Therapeutics (ATBPD), Antibe Therapeutics (ATBPD), Antibe Therapeutics (ATBPF), Epizyme (EPZM), Arcutis Biotherapeutics (ARQT), BioXcel Therapeutics (BTAI), Omeros (OMER), Organogenesis (ORGO) and Northwest Biotherapeutics (NWBO).
View all of CNCE's competitors.

What other stocks do shareholders of Concert Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Concert Pharmaceuticals investors own include Gilead Sciences (GILD), Eiger BioPharmaceuticals (EIGR), Exelixis (EXEL), ACADIA Pharmaceuticals (ACAD), Nektar Therapeutics (NKTR), TG Therapeutics (TGTX), Celldex Therapeutics (CLDX), Amicus Therapeutics (FOLD), Global Blood Therapeutics (GBT) and Intel (INTC).

Who are Concert Pharmaceuticals' key executives?

Concert Pharmaceuticals' management team includes the following people:
  • Mr. Richard H. Aldrich M.B.A., Mba, Co-Founder & Chairman (Age 67, Pay $83.52k)
  • Dr. Roger D. Tung, Co-Founder, CEO, Pres & Exec. Director (Age 61, Pay $882.85k)
  • Mr. Marc A. Becker, CFO & Principal Accounting Officer (Age 49, Pay $559.68k)
  • Dr. James V. Cassella, Chief Devel. Officer (Age 66, Pay $667.08k)
  • Ms. Nancy Stuart, Chief Operating Officer (Age 63)
  • Ms. Justine E. Koenigsberg, Sr. VP of Corp. Communications and Investor Relations
  • Mr. Jeffrey A. Munsie, Chief Legal Officer & Corp. Sec. (Age 44)
  • Dr. Ian Robert Silverman J.D., Ph.D., Sr. Legal Advisor (Age 68)

What is Concert Pharmaceuticals' stock symbol?

Concert Pharmaceuticals trades on the NASDAQ under the ticker symbol "CNCE."

How do I buy shares of Concert Pharmaceuticals?

Shares of CNCE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Concert Pharmaceuticals' stock price today?

One share of CNCE stock can currently be purchased for approximately $10.73.

How big of a company is Concert Pharmaceuticals?

Concert Pharmaceuticals has a market capitalization of $328.86 million and generates $1.08 million in revenue each year. The biotechnology company earns $-78,170,000.00 in net income (profit) each year or ($3.29) on an earnings per share basis. Concert Pharmaceuticals employs 70 workers across the globe.

What is Concert Pharmaceuticals' official website?

The official website for Concert Pharmaceuticals is www.concertpharma.com.

How can I contact Concert Pharmaceuticals?

Concert Pharmaceuticals' mailing address is 65 HAYDEN AVENUE SUITE 3000N, LEXINGTON MA, 02421. The biotechnology company can be reached via phone at 781-860-0045 or via email at [email protected]

This page was last updated on 1/21/2021 by MarketBeat.com Staff
Receive Analysts' Upgrades and Downgrades Daily

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.